HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)
MarketBeatHC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday.
HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday.